Related references
Note: Only part of the references are listed.Assessing the in vivo efficacy of biologic antiangiogenic therapies
Peter M. Wilson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
A. J. Zurita et al.
ANNALS OF ONCOLOGY (2012)
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Geoffrey Kim et al.
CANCER (2012)
Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab
David O. Bates et al.
CLINICAL CANCER RESEARCH (2012)
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Cody J. Peer et al.
CLINICAL CANCER RESEARCH (2012)
TUMOR METABOLISM AND PERFUSION IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: PRETREATMENT MULTIMODALITY IMAGING WITH H-1 MAGNETIC RESONANCE SPECTROSCOPY, DYNAMIC CONTRAST-ENHANCED MRI, AND [F-18]FDG-PET
Jacobus F. A. Jansen et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab
Erin R. Gardner et al.
INVESTIGATIONAL NEW DRUGS (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
F. Bertolini et al.
BRITISH JOURNAL OF CANCER (2011)
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
Lokesh Jain et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study
Lubomir Bodnar et al.
GYNECOLOGIC ONCOLOGY (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Proteomics and biomarkers in clinical trials for drug development
Jung-min Lee et al.
JOURNAL OF PROTEOMICS (2011)
Chemotherapy and targeted therapies for unresectable malignant mesothelioma
Ronan Joseph Kelly et al.
LUNG CANCER (2011)
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
J-M Lee et al.
BRITISH JOURNAL OF CANCER (2010)
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
Christina M. Annunziata et al.
CLINICAL CANCER RESEARCH (2010)
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
Lokesh Jain et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Imaging of Tumor Angiogenesis: Functional or Targeted?
Baris Turkbey et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2009)
Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development
Daniel S. W. Tan et al.
CANCER JOURNAL (2009)
Anticancer strategies involving the vasculature
Victoria L. Heath et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The lessons of GIST - PET and PET/CT: A new paradigm for imaging
Annick D. Van den Abbeele
ONCOLOGIST (2008)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays
Mary Winters et al.
PROTEOMICS (2007)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Experience with bevacizumab in the management of epithelial ovarian cancer
Robert A. Burger
JOURNAL OF CLINICAL ONCOLOGY (2007)
Imaging of angiogenesis: from microscope to clinic
DM McDonald et al.
NATURE MEDICINE (2003)
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging
PL Choyke et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2003)
Share Paper
